A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer

Purpose: Aberrant mTOR pathway and somatostatin receptor signaling are implicated in thyroid cancer and offer potential therapeutic targets. We assessed the clinical efficacy of everolimus and Pasireotide long-acting release (LAR) in radioiodine-refractory differentiated thyroid cancer (DTC) and med...

Full description

Bibliographic Details
Main Authors: Julie E. Bauman, Zhengjia Chen, Chao Zhang, James P. Ohr, Robert L. Ferris, Gerald M. McGorisk, Stephen Brandt, Sumathi Srivatsa, Amy Y. Chen, Conor E. Steuer, Dong M. Shin, Nabil F. Saba, Fadlo R. Khuri, Taofeek K. Owonikoko
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
thyroid cancer
somatostatin receptor
everolimus
pasireotide
combination
medullary carcinoma
Online Access:https://www.mdpi.com/2072-6694/14/11/2639

Internet

https://www.mdpi.com/2072-6694/14/11/2639

Similar Items